Search

Your search keyword '"Sugiura, Wataru"' showing total 2 results
Start Over "Sugiura, Wataru" Journal plos medicine Publisher public library of science
2 results on '"Sugiura, Wataru"'

1. Recommendations on data sharing in HIV drug resistance research

Author

Inzaule, Seth C., Siedner, Mark J., Little, Susan J., Avila-Rios, Santiago, Ayitewala, Alisen, Bosch, Ronald J., Calvez, Vincent, Ceccherini-Silberstein, Francesca, Charpentier, Charlotte, Descamps, Diane, Eshleman, Susan H., Fokam, Joseph, Frenkel, Lisa M., Gupta, Ravindra K., Ioannidis, John P.A., Kaleebu, Pontiano, Kantor, Rami, Kassaye, Seble G., Kosakovsky Pond, Sergei L., Kouamou, Vinie, Kouyos, Roger D., Kuritzkes, Daniel R., Lessells, Richard, Marcelin, Anne-Genevieve, Mbuagbaw, Lawrence, Minalga, Brian, Ndembi, Nicaise, Neher, Richard A., Paredes, Roger, Pillay, Deenan, Raizes, Elliot G., Rhee, Soo-Yon, Richman, Douglas D., Ruxrungtham, Kiat, Sabeti, Pardis C., Schapiro, Jonathan M., Sirivichayakul, Sunee, Steegen, Kim, Sugiura, Wataru, van Zyl, Gert U., Vandamme, Anne-Mieke, Wensing, Annemarie M.J., Wertheim, Joel O., Gunthard, Huldrych F., Jordan, Michael R., and Shafer, Robert W.

Subjects
United States. Centers for Disease Control and Prevention, United States. National Institutes of Health, Merck & Company Inc., Gilead Sciences Inc., Biological products industry, HIV (Viruses) -- Drug therapy, Rilpivirine, Drug resistance -- Drug therapy, Pharmaceutical industry, Biological sciences, World Health Organization
Abstract

Author(s): Seth C. Inzaule 1, Mark J. Siedner 2, Susan J. Little 3, Santiago Avila-Rios 4, Alisen Ayitewala 5, Ronald J. Bosch 6, Vincent Calvez 7, Francesca Ceccherini-Silberstein 8, Charlotte [...]

Published
2023
Full Text
View/download PDF

2. Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration.

Author

Kantor, Rami, Katzenstein, David A., Efron, Brad, Carvalho, Ana Patricia, Wynhoven, Brian, Cane, Patricia, Clarke, John, Sirivichayakul, Sunee, Soares, Marcelo A., Snoeck, Joke, Pillay, Candice, Rudich, Hagit, Rodrigues, Rosangela, Holguin, Africa, Ariyoshi, Koya, Bouzas, Maria Belen, Cahn, Pedro, Sugiura, Wataru, Soriano, Vincent, and Brigido, Luis F.

Subjects
HIV, DRUG resistance, ANTIRETROVIRAL agents, PROTEOLYTIC enzymes, REVERSE transcriptase
Abstract

Background The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate. Methods and Findings To assess the impact of HIV-1 subtype and antiretroviral treatment on the distribution of mutations in protease and reverse transcriptase, a binomial response model using subtype and treatment as explanatory variables was used to analyze a large compiled dataset of non-subtype- B HIV-1 sequences. Non-subtype-B sequences from 3,686 persons with well characterized antiretroviral treatment histories were analyzed in comparison to subtype B sequences from 4,769 persons. The non-subtype-B sequences included 461 with subtype A, 1,185 with C, 331 with D, 245 with F, 293 with G, 513 with CRF01_AE, and 618 with CRF02_AG. Each of the 55 known subtype B drug-resistance mutations occurred in at least one non-B isolate, and 44 (80%) of these mutations were significantly associated with antiretroviral treatment in at least one non-B subtype. Conversely, of 67 mutations found to be associated with antiretroviral therapy in at least one non-B subtype, 61 were also associated with antiretroviral therapy in subtype B isolates. Conclusion Global surveillance and genotypic assessment of drug resistance should focus primarily on the known subtype B drug-resistance mutations. INSET: Patient Summary. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results